{
    "title": "Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4242070/Nordic-Nanovector-sees-Non-Hodgkin-Lymphoma-treatment.html",
    "date": "2017-02-20",
    "keywords": [
        "nanovector",
        "drug",
        "market",
        "approval",
        "company",
        "costa",
        "percent",
        "fda",
        "probability",
        "december",
        "betalutin",
        "development",
        "camilla",
        "knudsenoslo",
        "biotech",
        "newcomer",
        "intrest",
        "firmwe",
        "talk",
        "lot",
        "data",
        "interest",
        "executive",
        "officer",
        "luigi",
        "stock",
        "partnership",
        "firm",
        "oslo",
        "commentsnanovector",
        "test",
        "phase",
        "candidate",
        "treatment",
        "lymphoma",
        "nhl",
        "way",
        "dose",
        "radiationif",
        "food",
        "administration",
        "time",
        "product",
        "end",
        "timeline",
        "assumption",
        "breakthrough",
        "therapy",
        "designation",
        "year",
        "study",
        "rituximab",
        "rituxan",
        "roche",
        "biogenrituximab",
        "standard",
        "care",
        "patent",
        "competition",
        "saidbrokerage",
        "abg",
        "sundal",
        "collier",
        "share",
        "buy",
        "price",
        "target",
        "crownsafter",
        "rise",
        "equity",
        "portfoliolast",
        "research",
        "legochem",
        "heidelberg",
        "unit",
        "germanys",
        "wilex",
        "ag",
        "value",
        "crowns1",
        "terje",
        "solsvikruth",
        "pitchford"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}